The Senate voted 51, 44 to confirm Dr. Erica Schwartz as the next CDC director, ending nearly a year without permanent leadership at the agency, but not before a key Republican demanded assurances she would put science over politics.
Schwartz, a Navy veteran and former Deputy Surgeon General, becomes the 22nd director of the Centers for Disease Control and Prevention and the first confirmed leader the agency has had since Susan Monarez was fired after less than a month on the job. The vote on August 5 fell largely along party lines, capping a confirmation process that nearly collapsed when the chairman of the Senate committee overseeing health policy balked at advancing her nomination.
Sen. Bill Cassidy, the Louisiana Republican who chairs the Senate Health, Education, Labor, and Pensions Committee, cast what amounted to the decisive vote. Cassidy had grown frustrated with Schwartz during her July 15 confirmation hearing, pressing her on whether she would operate independently from Health and Human Services Secretary Robert F. Kennedy Jr., a figure whose skepticism toward vaccines has drawn sharp criticism from public health professionals and members of his own party.
Cassidy ultimately came around after speaking privately with Schwartz and reviewing the transcript of her hearing testimony. At a subsequent committee meeting, he told colleagues he was satisfied she would hold her ground:
"We need a CDC director that will actually stand up to crazy, stupid things being said that undermine faith in immunization. I'm confident that she knows what she is doing and will stand against those who do not."
That endorsement cleared the path. But the fact that a Republican committee chairman had to extract personal guarantees before voting to confirm a Republican president's nominee tells you how deep the fault lines over vaccine policy run inside the administration's own coalition.
During her hearing, Sen. Bernie Sanders, the ranking Democrat on the HELP Committee, asked Schwartz directly whether she would remove a controversial CDC webpage that suggests a link between vaccines and autism, a page that public health experts say contradicts the agency's own research. Schwartz accepted that "overwhelming evidence" shows vaccines do not cause autism, but she stopped short of committing to take the page down.
On the broader question of independence from Kennedy, Schwartz drew on her military background. She told the committee:
"Senator, I have been in situations where I have had to go to my superiors in the military to have conversations, very difficult conversations, about things that may have been concerning to the troops or to the military personnel, and I will do the same with [Secretary Robert F. Kennedy Jr.]."
That answer did not fully satisfy Cassidy at the time. He wanted more than an analogy. But the behind-the-scenes follow-up, and HHS's decision to modify the CDC's autism-and-vaccines webpage, which Cassidy described as "a sign of good faith", apparently provided enough reassurance to move the nomination forward.
The Senate has been busy with high-stakes confirmation battles this session. Lawmakers recently advanced Jay Clayton toward a final vote for director of national intelligence, and similar partisan dynamics shaped those proceedings.
Schwartz is President Trump's third pick for CDC director in a year and a half. The first, Dr. David Weldon, failed to advance. The second, Susan Monarez, was confirmed in July 2025 only to be fired by Kennedy before she had served a full month. Monarez was reportedly removed for refusing to rubber-stamp Kennedy's vaccine agenda and for declining to fire high-ranking CDC officials whom the secretary opposed.
Both Kennedy and Monarez later appeared before Senate committees to address the ousting, a spectacle that underscored how unstable the agency's leadership had become. After Monarez's removal, Dr. Jay Bhattacharya, who already served as director of the National Institutes of Health, took on the acting CDC director role in February, stretching himself across two agencies.
The revolving door has taken a measurable toll. AP News reported that the CDC has lost more than 3,000 employees, over one-quarter of its workforce, through layoffs and resignations since Trump returned to office. That kind of institutional erosion does not reverse overnight, no matter who sits in the director's chair.
Confirmation fights have been a recurring theme across the administration's nominees. The weeks-long standoff over Todd Blanche's attorney general nomination followed a similar pattern: Republican holdouts demanding commitments before lending their votes.
Dr. Richard Besser, who served as acting CDC director during the Obama administration, offered a cautious assessment. He told ABC News he was willing to give Schwartz a chance, but laid out specific benchmarks he would use to judge her independence.
"I'm concerned that [Schwartz won't] be allowed to do her job, and worry that she will experience the same fate as Dr. Monarez. But I'm willing to be surprised. We definitely need an independent CDC director."
Besser pointed to three active crises as immediate tests: whether Schwartz would use her public voice to encourage measles vaccination, whether she would press for international support to contain an Ebola outbreak in Africa, and how she would coordinate the federal response to a cyclospora outbreak, a parasitic illness linked to contaminated lettuce that has spread across multiple states.
Dr. Georges Benjamin of the American Public Health Association struck a similar note, saying the agency "desperately needs stability, experienced leadership and a steadfast commitment to science" after two years of turmoil. A statement from the National Public Health Coalition was blunter: "Now, Dr. Schwartz needs to prove that her leadership will serve science and not the whims of politicians."
Those are fair demands. The CDC exists to protect Americans from disease. When leadership instability, political interference, and workforce losses hollow out the agency, ordinary people, not bureaucrats, not politicians, bear the consequences. Families dealing with a parasitic outbreak in their grocery store lettuce do not care about Beltway turf wars between a cabinet secretary and the agency heads beneath him.
Partisan dynamics have shaped nearly every major Senate action this year, from spending bill votes to committee-level clashes over policy amendments.
On paper, Schwartz's résumé is strong. She earned her medical degree from Brown University, served in the Navy until 2005, held the post of Coast Guard Chief Medical Officer, worked in the U.S. Public Health Service Commissioned Corps, and served as Deputy Surgeon General from 2019 through early 2021. Trump called her "incredibly talented" when he announced the nomination in April.
But Monarez had credentials, too. She lasted less than a month. The question hanging over Schwartz's tenure is not whether she knows medicine, it is whether she can navigate a political environment where her own cabinet superior has publicly questioned the safety of widely used vaccines, and where disagreeing with him has already cost one director her job.
Cassidy's intervention offers a partial answer. The chairman made clear he expected Schwartz to defend immunization science, and he extracted that commitment before lending his vote. Whether that commitment holds under sustained pressure from Kennedy remains the central unanswered question.
Just The News confirmed the August 5 vote tally at 51, 44, with five senators not recorded as voting. Which senators, if any, crossed party lines was not disclosed in available reporting.
Senate Republicans have shown a willingness to hold their own party's nominees accountable this session, as the Blanche confirmation saga demonstrated. Cassidy's stand on the Schwartz vote fits that pattern.
Schwartz inherits an agency that has bled a quarter of its workforce, cycled through three nominees, and operated without a permanent director for close to a year, all while active disease outbreaks demand coordinated federal response. The measles vaccine debate, the Ebola situation in Africa, and the cyclospora outbreak spreading domestically are not theoretical problems. They are happening now.
Conservatives rightly demanded accountability and reform at the CDC after the agency's credibility collapsed during the pandemic. Bloated bureaucracy, inconsistent guidance, and mission creep earned the scrutiny. But accountability requires stable, competent leadership empowered to make science-based decisions, not a revolving door driven by internal political disputes that leave the agency rudderless for months at a time.
Schwartz says she will have the hard conversations. Americans dealing with real outbreaks in real communities need her to mean it.
